GlaxoSmithKline | GSK - Current Assets


GlaxoSmithKline reported GBP17.9B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Alcon AG USD 6.62B 4M Jun/2026
Almirall EUR 747.1M 33.12M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
argenx SE USD 8.07B 1.17B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bayer EUR 33.64B 1.66B Jun/2026
Biogen USD 7.58B 278.7M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Fresenius EUR 11.61B 456M Jun/2026
Fresenius Medical Care EUR 7.69B 418.66M Jun/2026
Genmab DKK 2.8B 228M Jun/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
GRIFOLS EUR 5.31B 51M Jun/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
Merck EUR 13.77B 393M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Orion EUR 1.34B 139.5M Sep/2026
Pfizer USD 41.36B 1.46B Jun/2026
Philips EUR 9.33B 454M Jun/2026
Recordati EUR 1.76B 29.78M Jun/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Smith & Nephew USD 4.39B 240M Jun/2026
UCB EUR 6.05B 733M Dec/2025